Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer
2022 Journal of Gastrointestinal Oncology. All rights reserved..
Background: Nutritional status is strongly associated to prognosis in metastatic gastrooesophageal junction (mGOJ)/gastric cancer (GC) patients. The aim of the present study was to develop an immune-checkpoint inhibitor (ICI)-specific nutritional index (NI).
Methods: Ten serum and anthropometric nutritional markers derived from blood tests or CT scans were analyzed at baseline in patients treated with second-line ICI and correlated with overall survival (OS). An ICI-specific NI (the NUTRIICI) was developed with its specificity assessed in an independent group of patients treated with standard second-line chemotherapy.
Results: From June 2014 to December 2018, 57 mGOJ/GC patients (14 females, 43 males) with a median(m) age of 61 years (range 29-85) received ICI as second-line therapy (Pembrolizumab n=26, Nivolumab n=16, Avelumab n=15). Among the 10 analyzed variables, Onodera's prognostic NI (PNI) ≤33 and waist-to-hip (WHR) <1 were independent predictors of OS and used to build the NUTRIICI. Patients with both favorable factors (i.e., PNI >33 and WHR ≥1, comparator group) had a mOS of 18.0 vs. 6.7 months of patients with one unfavorable factor (either PNI ≤33 or WHR <1, Hazard Ratio, HR 3.06), vs. 1.3 months of patients with both unfavorable factors (HR 17.56), overall P<0.0001. In the independent group of patients treated with standard chemotherapy NUTRIICI was not associated with prognosis (P=0.57).
Conclusions: NUTRIICI is the first ICI-specific NI for mOGJ/GC patients receiving second-line ICI. A validation in larger cohorts is strongly encouraged.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of gastrointestinal oncology - 13(2022), 5 vom: 10. Okt., Seite 2072-2081 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morelli, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 19.11.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/jgo-22-217 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349020213 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349020213 | ||
| 003 | DE-627 | ||
| 005 | 20231226041641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/jgo-22-217 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349020213 | ||
| 035 | |a (NLM)36388663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morelli, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.11.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2022 Journal of Gastrointestinal Oncology. All rights reserved. | ||
| 520 | |a Background: Nutritional status is strongly associated to prognosis in metastatic gastrooesophageal junction (mGOJ)/gastric cancer (GC) patients. The aim of the present study was to develop an immune-checkpoint inhibitor (ICI)-specific nutritional index (NI) | ||
| 520 | |a Methods: Ten serum and anthropometric nutritional markers derived from blood tests or CT scans were analyzed at baseline in patients treated with second-line ICI and correlated with overall survival (OS). An ICI-specific NI (the NUTRIICI) was developed with its specificity assessed in an independent group of patients treated with standard second-line chemotherapy | ||
| 520 | |a Results: From June 2014 to December 2018, 57 mGOJ/GC patients (14 females, 43 males) with a median(m) age of 61 years (range 29-85) received ICI as second-line therapy (Pembrolizumab n=26, Nivolumab n=16, Avelumab n=15). Among the 10 analyzed variables, Onodera's prognostic NI (PNI) ≤33 and waist-to-hip (WHR) <1 were independent predictors of OS and used to build the NUTRIICI. Patients with both favorable factors (i.e., PNI >33 and WHR ≥1, comparator group) had a mOS of 18.0 vs. 6.7 months of patients with one unfavorable factor (either PNI ≤33 or WHR <1, Hazard Ratio, HR 3.06), vs. 1.3 months of patients with both unfavorable factors (HR 17.56), overall P<0.0001. In the independent group of patients treated with standard chemotherapy NUTRIICI was not associated with prognosis (P=0.57) | ||
| 520 | |a Conclusions: NUTRIICI is the first ICI-specific NI for mOGJ/GC patients receiving second-line ICI. A validation in larger cohorts is strongly encouraged | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a nutrition | |
| 700 | 1 | |a Formica, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Patrikidou, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rofei, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Shiu, Kai Keen |e verfasserin |4 aut | |
| 700 | 1 | |a Riondino, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Argirò, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Floris, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ferlosio, Amedeo |e verfasserin |4 aut | |
| 700 | 1 | |a Orlandi, Augusto |e verfasserin |4 aut | |
| 700 | 1 | |a Roselli, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Arkenau, Hendrik-Tobias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of gastrointestinal oncology |d 2010 |g 13(2022), 5 vom: 10. Okt., Seite 2072-2081 |w (DE-627)NLM209547685 |x 2078-6891 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:5 |g day:10 |g month:10 |g pages:2072-2081 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/jgo-22-217 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 5 |b 10 |c 10 |h 2072-2081 | ||